Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01970358 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
A Phase 1 study, sponsored by Patrick Ott, MD, PhD.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01970358 is a Phase 1 study that has completed, run by Patrick Ott, MD, PhD. The registered enrollment target is 15 participants.
The verdict
NCT01970358, a Phase 1 study, has completed, sponsored by Patrick Ott, MD, PhD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This research study is evaluating a new type of melanoma vaccine called "Personalized NeoAntigen Cancer Vaccine". The purpose of this study is to determine if it is possible to make and administer safely a vaccine against melanoma by using information gained from specific characteristics of the participant's own melanoma. It is known that melanomas have mutations (changes in genetic material) that are specific to an individual patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. It is possible that these proteins used in a vaccine may induce strong immune responses, which may help the participant's body fight any tumor cells that could cause the melanoma to come back in the future. The study will examine the safety of the vaccine when given at several different time points and will examine the participant's blood cells for signs that the vaccine induced an immune response.
Interventions
- BIOLOGICAL Poly-ICLC
- BIOLOGICAL Peptides
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-04 |
| Est. Completion | 2018-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01970358
The ClinicalTrials.gov registry entry for NCT01970358 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Patrick Ott, MD, PhD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Poly-ICLC is the first listed.
NCT01970358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01970358 about?
NCT01970358 is a clinical study titled "A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma". This research study is evaluating a new type of melanoma vaccine called "Personalized NeoAntigen Cancer Vaccine". The purpose of this study is to determine if it is possible to make and administer safely a vaccine against melanoma by using information gained from specific characteristics of the part...
What is the current status of trial NCT01970358?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-04. Estimated completion is 2018-06.
What interventions are being tested in trial NCT01970358?
The interventions under investigation include: Poly-ICLC (BIOLOGICAL), Peptides (BIOLOGICAL).
Who is sponsoring clinical trial NCT01970358?
This trial is sponsored by Patrick Ott, MD, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.